期刊文献+

Eph A5在卵巢癌组织中的表达及与临床特征和预后的关系 被引量:3

Expression of Eph A5 in ovarian carcinoma and its relationship with clinical features and prognosis of patients
下载PDF
导出
摘要 目的探讨浆液性卵巢癌组织中酪氨酸蛋白激酶A5受体(Eph A5)的表达水平变化、与患者临床病理学特征及预后的关系。方法浆液性卵巢癌病理组织标本94例作为恶性组、选取同期收集的卵巢浆液性囊腺瘤组织标本30例作为良性组,采用免疫组化染色观察2组标本中Eph A5蛋白表达差异,并采用Logistic回归分析浆液性卵巢癌患者的预后影响因素。结果恶性组的Eph A5蛋白阳性表达率高于良性组(P<0.05);浆液性卵巢癌组织中Eph A5蛋白表达与肿瘤分化程度、FIGO分期、淋巴结转移具有相关性(P<0.05);Eph A5蛋白阳性表达的浆液性卵巢癌患者3年生存率高于阴性表达患者(P<0.05);Eph A5蛋白阳性表达对浆液性卵巢癌患者远期预后有利(OR=0.629,P<0.05),低分化、FIGO分期增高、淋巴结转移时患者远期预后的不良因素(OR=1.833,OR=1.467,OR=1.625,P<0.05)。结论浆液性卵巢癌组织中Eph A5蛋白的表达水平上调,与患者的肿瘤分化程度、FIGO分期、淋巴结转移具有相关性,是患者远期预后的保护因素。 Objective To investigate the expression of tyrosine kinase A5 receptor( Eph A5) in serous ovarian cancer tissues and its relationship with clinicopathological features and prognosis of patients. Methods Ninety-four cases of serous ovarian cancer tissues collected in our hospital from January 2010 to December 2013 were enrolled as malignant group,meanwhile,30 cases of ovarian serous cystadenoma tissues were served as benign group. The expression levels of Eph A5 protein were detected by immunohistochemical staining for both groups,moreover the influencing factors on prognosis of patients with serous ovarian cancer were analyzed by Logistic regression analysis. Results The positive expression rate of Eph A5 protein in malignant group was 74. 47%,which was significatly higher than that( 6. 67%) in benign group( P〈0. 05),moreover,the expression levels of Eph A5 protein in serous ovarian cancer tissues were closely correlated to tumor differentiation degree,FIGO stage and lymph node metastasis( P〈0. 05). The 3-year survival rate in patients with positive expression of Eph A5 protein was 65. 71%,which was significantly higher than that( 41. 67%) in patients with negative expression of Eph A5 protein P〈0. 05). The positive expression of Eph A5 protein was beneficial for the long-term prognosis of patients with serous ovarian cancer( OR = 0. 629,P〈0. 05),however,lower differentiation,higher FIGO stage and lymph node metastasis were adverse factors influencing long-term prognosis of patients( OR = 1. 833,1. 467,1. 625,respectively,P〈0. 05). Conclusion The up-regulation of expression levels of Eph A5 protein in serous ovarian carcinoma tissues is closely correlated to tumor differentiation degree,FIGO stage and lymph node metastasis,which is a protective factor of long-term prognosis of patients.
出处 《河北医药》 CAS 2018年第2期255-257,共3页 Hebei Medical Journal
关键词 浆液性卵巢癌 酪氨酸蛋白激酶A5受体 病理学特 预后 serous ovarian cancer tyrosine protein kinase A5 receptor pathological characteristics prognosis
  • 相关文献

参考文献10

二级参考文献157

  • 1冯梅,陈桂林,李秀华,陈琴,郭慈仁.复发性卵巢上皮癌67例临床分析[J].福建医药杂志,2006,28(6):31-32. 被引量:2
  • 2唐军,赖娟,耿京,吕君.术前诊断卵巢交界性肿瘤的超声特征[J].中国妇产科临床杂志,2007,8(3):172-174. 被引量:18
  • 3Maniotis AJ,Folberg R,Hess A,et al.Vascular channel formation by human melanoma cells in vivo and in vitro:vasculogenic mimicry[J].Am J Pathol,1999,155(3):739-752.
  • 4Sun B,Zhang S,Zhang D,et al.Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer[J].Clin Cancer Res,2008,14(21):7050-7059.
  • 5Byrne AM,Bouchier-Hayes DJ,Harmey JH.Angiogenic and cell survival functions of vascular endothelial growth factor[J].J Cell Mol Med,2005,9(4):777-794.
  • 6Sun B,Zhang D,Zhang S,et al.Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma[J].Cancer Lett,2007,249(2):188-197.
  • 7Brantley-Sieders DM,Fang WB,Hicks DJ,et al.Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression[J].FASEB J,2005,19(13):1884-1886.
  • 8Zelinski DP,Zantek ND,Stewart JC,et al.EphA2 overexpression causes tumorigenesis of mammary epithelial cells[J].Cancer Res,2001,61(5):2301-2306.
  • 9Walker-Daniels J,Hess AR,Hendrix MJ,et al.Differential regulation of EphA2 in normal and malignant cells[J].Am J Pathol,2003,162(4):1037-1042.
  • 10Ireton RC,Chen J.EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics[J].Curr Cancer Drug Targets,2005,5(3):149-157.

共引文献30

同被引文献25

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部